TriangleNCT02612779 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From first dose to study completion date (up to approximately 50 months)
What was measured
PFS is defined as the time from first dosing date to the date of the first documented progression or death due to any cause, whichever occurs first. Progression is determined per International Myeloma Working Group (IMWG) uniform criteria. Participants who die without a reported prior progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable assessment. Participants who did not have any on study efficacy assessments and did not die were censored on the first dosing date. Participants who switched to subsequent therapy prior to documented progression were censored on the date of the last evaluable assessment prior to the initiation of the new therapy.
Analysis population: All treated participants
Groups in this outcome
EN Cohort
Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.
| Group | Source count |
|---|---|
| EN Cohort | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| EN Cohort | 1.9 | Not reported | 0.6 | NA | Upper limit not estimable |
Complete source fields
- classes
- categories
- measurements
- comment
- Upper limit not estimable
- group Id
- OG000
- lower Limit
- 0.6
- upper Limit
- NA
- value
- 1.9
- denoms
- counts
- group Id
- OG000
- value
- 6
- units
- Participants
- description
- PFS is defined as the time from first dosing date to the date of the first documented progression or death due to any cause, whichever occurs first. Progression is determined per International Myeloma Working Group (IMWG) uniform criteria. Participants who die without a reported prior progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable assessment. Participants who did not have any on study efficacy assessments and did not die were censored on the first dosing date. Participants who switched to subsequent therapy prior to documented progression were censored on the date of the last evaluable assessment prior to the initiation of the new therapy.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.
- id
- OG000
- title
- EN Cohort
- param Type
- MEDIAN
- population Description
- All treated participants
- reporting Status
- POSTED
- time Frame
- From first dose to study completion date (up to approximately 50 months)
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice